Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Inhaler Stories

2010-05-05 07:00:00

REDWOOD CITY, Calif., May 5 /PRNewswire/ -- Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced four upcoming poster presentations at the Annual Meeting of the American Thoracic Society (ATS) to be held at the Ernest N. Morial Convention Center in New Orleans from May 14-19, 2010. Results from Pearl's Phase 1 safety and pharmacokinetics study of...

2010-04-29 13:36:00

PHILADELPHIA, April 29 /PRNewswire/ -- In the United States alone, over 22 million people, including more than six million children, are known to have asthma, which is a leading cause of hospital emergency department visits and school absenteeism. In response to these alarming statistics, and in an effort to raise public awareness of the risks faced everyday by those living with asthma, Teva Respiratory is supporting National Asthma and Allergy Awareness Month as a Platinum sponsor of the...

2010-04-26 08:45:00

WALTHAM, Mass., April 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite increased competition from several emerging agents, GlaxoSmithKline's Advair will remain surveyed pulmonologists' and primary care physicians' (PCPs) favored fixed-dose long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination inhaler through 2013 for the treatment of asthma and chronic obstructive...

2010-04-15 08:30:00

ST. PAUL, Minn., April 15 /PRNewswire-Asia/ -- 3M Drug Delivery Systems recently advanced its participation in the Asian market with a sponsorship of the Asia Pharma R&D Leaders 2010 event, held March 4 and 5 in Shanghai, China. The event, organized by Global Leaders Institute, the leading life science event producer in China, brings together leading pharmaceutical industry professionals, policymakers, and academics to discuss Asia's role in the manufacturing, research and development...

2010-04-13 17:12:00

RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD)...

2010-04-13 12:59:00

SILVER SPRING, Md., April 13 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced, in accordance with longstanding U.S. obligations under the Montreal Protocol on Substances that Deplete the Ozone Layer, seven metered-dose inhalers (MDI) used to treat asthma and chronic obstructive pulmonary disease (COPD) will be gradually removed from the U.S. marketplace. These inhalers contain ozone-depleting chlorofluorocarbons (CFCs), which are propellants that move...

2010-04-13 12:49:00

SILVER SPRING, Md., April 13 /PRNewswire-USNewswire/ -- The Food and Drug Administration (FDA) says that seven metered dose inhalers that contain chlorofluorocarbons (CFCs) are being phased out in the United States. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) These inhalers use CFCs as propellants to spray the medicine out of the inhaler so patients can breathe the medicine into their lungs. They're used for the treatment of asthma or chronic obstructive pulmonary...

2010-03-18 10:11:00

PITTSBURGH, March 18 /PRNewswire/ -- ChemImage, a world leader in chemical imaging products and services, will present the results of an ingredient-specific particle sizing (ISPST) study on a combination Metered Dose Inhaler product at Respiratory Drug Delivery (RDD) 2010 (www.rddonline.com). This conference will take place from April 25th - 29th in Orlando, Florida and will feature thought leaders discussing current biological and pharmaceutical issues related to nasal and respiratory...

2010-03-11 16:03:00

WILMINGTON, Del., March 11 /PRNewswire-FirstCall/ -- On March 10-11, 2010, the Joint Advisory Committees of the U.S. Food and Drug Administration (FDA) -- including the Pulmonary-Allergy Drugs and the Drug Safety and Risk Management Advisory Committees -- discussed the design of post-marketing safety studies for long-acting beta-agonist (LABA)-containing products in the U.S., including SYMBICORT(® )(budesonide/formoterol fumarate dihydrate). (Logo:...

2010-03-08 16:55:15

AUGUSTA, Ga. -- An asthma program specifically tailored to teens could help those in rural areas manage their disease and avoid potentially fatal complications, Medical College of Georgia researchers say. Black males have a death rate from asthma that is six times greater than their white counterparts, and Dr. Dennis Ownby, chief in the MCG School of Medicine Section of Allergy and Immunology, believes asthma rates are as bad in rural areas as they are in inner cities. "The prevalence is...